Ceritinib-d7

• Description :

  Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

• Product Name Alternative :

  LDK378 D7

• UNSPSC :

  12352005

• Target :

  Anaplastic lymphoma kinase (ALK) ; IGF-1R; Insulin Receptor; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Others; Protein Tyrosine Kinase/RTK

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Endocrinology

• Purity :

  98.00

• Solubility :

  10 mM in DMSO|DMSO : ≥ 12.5mg/mL

• Smiles :

  CC1=C(C2CCNCC2)C=C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3)=C1

• Molecular Formula :

  C28H29D7ClN5O3S

• Molecular Weight :

  565.18

• References & Citations :

  [1]Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2- (2-isopropoxy-5-methyl-4- (piperidin-4-yl) phenyl) -N4- (2- (isopropylsulfonyl) phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56 (14) :5675-90.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1632484-77-5]